Evidence map›Paper›PMID 29193563›Full record

Trial reportEuropean journal of heart failure2018

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.

Ulrik M Mogensen, Lars Køber, Pardeep S Jhund, Akshay S Desai, Michele Senni, Søren L Kristensen, Andrej Dukát, Chen-Huan Chen, Felix Ramires, Martin P Lefkowitz and 8 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 53 citations in OpenAlex.

  1. Effects of Sacubitril/Allisartan versus Olmesartan on serum uric acid in Chinese patients with hypertension and hyperuricaemia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Potential uric acid-lowering effect of sacubitril/valsartan.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  6. Losartan, uric acid, and cardiometabolic disease: beyond blood pressure control.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  7. Article
  8. Article
  9. Therapeutic approaches to hypertension complicated by hyperuricemia: insights from a joint symposium.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 10 countries.

Ulrik M MogensenBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Lars KøberRigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Pardeep S JhundBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Akshay S DesaiCardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Michele SenniCardiology, Heart Failure and Heart Transplant Unit, Hospital Papa Giovanni XXIII, Bergamo, Italy.
Søren L KristensenBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Andrej DukátSecond Department of Internal Medicine, Comenius University, Bratislava, Slovakia.
Chen-Huan ChenDepartment of Medicine, National Yang-Ming University, Republic of China, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
Felix RamiresHeart Institute (InCor) - University of São Paulo, Medical School, Brazil.
Martin P LefkowitzNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Margaret F PrescottNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Victor C ShiNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Jean L RouleauInstitut de Cardiologie, Université de Montréal, Montréal, Canada.
Scott D SolomonCardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Karl SwedbergDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden and National Heart and Lung Institute, Imperial College London, London, UK.
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
PARADIGM-HF Investigators and Committees
Brigham and Women's Hospital · USCopenhagen University Hospital · DKNovartis (United States) · USUniversity of Glasgow · GBBaylor University Medical Center · USComenius University Bratislava · SKNational Yang Ming Chiao Tung University · TWNovartis (Switzerland) · CHOspedale Papa Giovanni XXIII · ITRigshospitalet · DKUniversidade de São Paulo · BRUniversité de Montréal · CAUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsElevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF. METHODS AND

resultsThe association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1-Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide. Change in SUA from baseline over 12 months was also evaluated in each treatment group. Patients in Q5 (SUA ≥8.6 mg/dL) compared with Q1 (<5.4 mg/dL) were younger (62.8 vs. 64.2 years), more often male (88.7% vs. 63.1%), had lower systolic blood pressure (119 vs. 123 mmHg), lower eGFR (57.4 vs. 76.6 mL/min/1.73 m

conclusionSerum uric acid concentration was an independent predictor of worse outcomes after multivariable adjustment in patients with HFrEF. Compared with enalapril, sacubitril/valsartan reduced SUA and improved outcomes irrespective of SUA.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDouble-Blind MethodDrug CombinationsFemaleFollow-Up StudiesGlomerular Filtration RateHeart FailureHumansMaleMiddle AgedNeprilysinPrognosisStroke VolumeAminobutyratesAngiotensin Receptor AntagonistsBiomarkersBiphenyl CompoundsDrug CombinationsNeprilysinsacubitril and valsartan sodium hydrate drug combinationTetrazolesUric AcidValsartanAngiotensinHeart failureMortalityNeprilysinUric acid

Identifiers

PMID29193563
PMCPMC6607477
OpenAlexW2773999918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.